Axsome Therapeutics said the FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease, expanding the drug's potential use. The approval was supported by the Phase 3 ADVANCE-1 and ACCORD-2 clinical program. The news is positive for AXSM and could modestly support shares, though it is company-specific rather than sector-wide.
Axsome Therapeutics said the FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease, expanding the drug's potential use. The approval was supported by the Phase 3 ADVANCE-1 and ACCORD-2 clinical program. The news is positive for AXSM and could modestly support shares, though it is company-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.72
Ticker Sentiment
